Article

Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T cell responses during chronic viral infection

2026-04-14

Abstract excerpt

<h4>ABSTRACT</h4> Interleukin-2 (IL-2) remains an attractive cytokine for enhancing antigen-specific CD8 T cell responses in cancer immunotherapy, but systemic toxicity hinders its broad clinical application. To address this, various IL-2-based therapeutics have been engineered with altered IL-2 receptor bias or targeted delivery to tumors, the tumor microenvironment, or immune cell populations. Ideally, IL-2 sig...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2bad0e80-d25b-5cfb-aa3a-6c3f01f21b8d
DOI: 10.64898/2026.04.13.718150

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T cell responses during chronic viral infectionDOI 10.64898/2026.04.13.718150Read

Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1Semantic proximity Read

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.Semantic proximity Read

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cellsSemantic proximity Read

IL-2 enhances effector function but suppresses follicular localization of CD8 <sup>+</sup> T cells in chronic infectionSemantic proximity Read

Regulatory T cell expansion by a highly CD25-dependent IL-2 mutein arrests ongoing autoimmunitySemantic proximity Read

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protectionSemantic proximity Read

Divergent effects of a Treg-selective IL-2 mutein on Influenza specific T cell responsesSemantic proximity Read

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read

New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseasesSemantic proximity Read

An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice.Semantic proximity Read

An IL-2 mutein increases IL-10 and CTLA-4-dependent suppression of dendritic cells by regulatory T cellsSemantic proximity Read

Synergistic activity of IL-2 mutein with tolerogenic ImmTOR nanoparticles leads to massive expansion of antigen-specific Tregs and protection against autoimmune diseaseSemantic proximity Read